A Practical Guide to MiFID II

Across Europe, the investment industry is preparing for the introduction of a revised Markets in Financial Instruments Directive (MiFID II) on 3 January 2018.

The biggest change under the new rules will be the requirement for fund management companies to explain clearly to their investors how much of their money is spent on research. This will inevitably impact how companies in the healthcare sector communicate with investors.


The question facing both sides is not only how to value investment research, but who will ultimately pay for it? Will smaller companies still see the same level of investor access and research?


Listen in to learn more about these new regulations, the direct impact for investors and biotech companies, and advice on how to proceed.




Introduction from the BIA

Explanation of MIFID II

  • What difference will this make to companies?
  • How does this affect relationships with the US?

What does this mean practically for private and listed companies?

  • How will investment research be affected?
  • Pros and Cons of company sponsored research
  •  How things will change practically for those involved?
  • What key issues should be discussed at Board level regarding MIFID II?



Find more information and speakers here!

Event Details


Tuesday, December 5, 2017 (10:00 h - 12:00 h)


Online Webinar




UK BioIndustry Association

2017-12-05 10:00:00 2017-12-05 12:00:00 Europe/Brussels A Practical Guide to MiFID II Online Webinar <p>UK BioIndustry Association</p>

More info?

For any further information about this event, please do not hesitate to get in touch with our Event Coordinator

Alternate Text

Lissa Van Hecke

Event Coordinator

| |

Interested in a regular update of the Life Sciences and biotech sector in Flanders?